US10189811B2

US10189811B2 - Method for preparing the anhydrous crystalline form of isoniazid-derived hydrazone, thus produced cristalline polymorph of the anhydrous form, use thereof for the treatment of Alzheimer's disease, parkinsonism and other neurodegenerative disorders, and pharmaceutical composition

Info

Publication number: US10189811B2
Application number: US15/106,181
Authority: US
Inventors: Nicolás Adrián Rey; Leonardo Viana de Freitas
Original assignee: Faculdades Catolicas Associacao Sem Fins Lucrativos
Current assignee: Faculdades Catolicas Associacao Sem Fins Lucrativos Mantenedora Da Pontificia Universidade Catolica; Faculdades Catolicas Associacao Sem Fins Lucrativos
Priority date: 2013-12-20
Filing date: 2014-06-06
Publication date: 2019-01-29
Anticipated expiration: 2034-06-06
Also published as: BR102013033006A2; US20190106408A1; EP3085691A1; US20170158665A1; WO2015089599A1; US10316019B2; EP3085691A4

Abstract

The present invention relates to the method for preparing the anhydrous crystalline form of isoniazid-derived hydrazone (8-hydroxyquinoline-2-carboxaldehyde isonicotinoyl hydrazone), to the thus produced polymorph and to the use thereof for the treatment of Alzheimer's disease and parkinsonism, inter alia, and to a pharmaceutical composition.

Description

FIELD OF THE INVENTION

The present invention regards the preparation method of the anhydrous crystalline form of an isoniazid-derived hydrazone (namely, 8-hydroxyquinoline-2-carboxaldehyde isonicotinoyl hydrazone, or INHHQ), the polymorph produced and its use, in any pharmaceutical composition, for the treatment of Alzheimer's and Parkinson's diseases, as well as other neurodegenerative disorders.

BACKGROUND OF THE INVENTION

With the general increase in life expectancy recorded in recent times, especially in developed countries, the prevalence of certain neurodegenerative diseases has been observed. Alzheimer's disease (AD), first characterized in 1906 by the german neuropathologist Alois Alzheimer, is currently the most common one. It is a primarily age-related disease and the most common cause of dementia in older people. Dementia is characterized by progressive loss of memory and cognitive functions, among other diagnostic criteria, being most of them present in the Diagnostic and Statistical Manual of Mental Disorders and described on the National Institute of Neurological and Communicative Disorders Association.

The disease has two general classifications: 1) late onset, which occurs with the highest incidence at about 60 years of age, and 2) early onset, occurring around 40 years. In the US and Great Britain, it represents about 50% of cases of dementia, being estimated that it is the fourth leading cause of deaths of elderly in these countries. Regarding the neuropathological aspect, patients show diffuse cortical atrophy, presence of senile plaques and neurofibrillary tangles, neurovascular degeneration and neuronal loss.

These senile plaques are characterized mainly by the presence of fibrillar deposits of β-amyloid peptide (Aβ), consisting of approx. 40 amino-acid residues. It has been observed high concentration of physiological metal ions such as Zn²⁺ and Cu²⁺, in these plaques, which is considered indicative that the interaction of Aβ with these biometais is at the heart of events that lead to aggregation and toxicity of this peptide. The ferric ions, in turn, have also been related to the aggregation of neurofibrillary tangles, in addition to contributing to the oxidative processes that occur in the nerve cells of the body. Something similar occurs in Parkinson's disease with the protein α-synuclein.

The already approved drugs for the treatment of AD are intended to combat deficits associated with reduced cerebral function and fall into two classes: acetylcholinesterase inhibitors and inhibitors of NMDA (N-Methyl-D-Aspartate) receptors. Such drugs seem to act in enhancing the remain of the cognitive function, however, are not able to prevent the progression of the disease, being, therefore, important the development of new therapeutic agents that hold the advance of neurodegeneration as well as, as far as possible, promote their regression. In this sense, an interesting approach is to obtain compounds that inhibit, specifically, abnormal metal-protein interactions. This class of drugs is known as MPACs (metal-protein attenuating compounds) and relate to the allocation and distribution normalization of physiological metal ions.

A classic example is the clioquinol (CQ or PBT1), a substance belonging to the group of 8-hydroxyquinolines, which, however, was abandoned due to certain unwanted side effects, such as subacute myelo-optic neuropathy.

Structure of clioquinol (5-chloro-7-iodo-8-hydroxyquinoline)

8-hydroxyquinoline-2-carboxaldehyde isonicotinoyl hydrazone (or INHHQ) was first described in a series of publications from the year 2009, in which its interactions with some rare earths ions, namely, dysprosium(III), europium(III), holmium(III), neodymium(III), and ytterbium(III) were examined. Erbium(III) and terbium(III) complexes were reported in 2010, while the samarium(III) compound was described in 2011. In those works, its rare earths complexes, and not INHHQ itself, were proposed as potential anticancer drugs, since they bind to DNA through an intercalation mechanism, besides they possess antioxidant properties, scavenging hydroxyl and superoxide radicals. Although the method of preparation described by the authors of those papers, Liu & Yang, is similar to the one employed by us, some experimental details are different. Mainly, the use of acid catalysis (drops of concentrated hydrochloric acid) allow us to reduce the reflux period to just an hour. On the other hand, and more important yet, the use of methanol PA ACS (99.8%) in the recrystallization step, instead of the methanol:water 80:20 used by the Chinese authors, lead to the preparation of the anhydrous crystalline form of the compound, which is completely original. Although this is not commented in the original articles, data suggest that the Chinese authors worked with an hydrated form of INHHQ, different from the one obtained by us, which can be clearly seen in the major differences between the melting points of the compounds, as well as between the vibrational (FTIR and Raman) spectra of both samples. Besides, application of INHHQ in the treatment of neurodegenerative diseases is completely new.

The anhydrous crystalline form described herein is characterized by its melting point, elemental analysis, crystal structure (single-crystal diffraction), powder diffraction pattern, and vibrational spectra.

BRIEF DESCRIPTION OF THE DRAWINGS

The present invention will hereinafter be illustrated with reference to the attached figures, which represent:

FIG. 1: ORTEP representation of the compound INHHQ, showing the identification scheme of the constituent atoms;

FIG. 2: Perspective views of INHHQ showing: (a) the hydrogen-bonding network, (b) the π-π and the O1-H12 . . . π stacking interactions and (c) the 3D crystalline packing along the crystallographic axis a;

FIG. 3: Simulated and experimental X-ray diffractograms for INHHQ;

FIG. 4: Most stable calculated structure in the gas-phase (Conf. 5). Level of theory: B3LYP/6-311+G (d,p);

FIG. 5: FTIR (above) and Raman (below) spectra of INHHQ;

FIG. 6: 2D ¹H×¹⁵N HSQC contour plots showing that the addition of INHHQ (4 eq.) to a mixture containing the β-amyloid peptide and Zn(II) (1 eq.) leads to a partial intensity recovery for all Aβ signals, which can be considered as an indicative that the hydrazone INHHQ weakens Zn(II)-Aβ interactions;

FIG. 7: ¹H NMR spectra showing that the addition of INHHQ (4 eq.) to a mixture containing α-synuclein and Cu(II)/Cu(I) (1 eq.) leads to the recovery of the original methionine signals' position; it is worth noting that methionine residues are the interaction point of copper with α-synuclein, which constitutes an indicative that INHHQ weakens Cu(II) or Cu(I)-α-synuclein interactions.

BRIEF DESCRIPTION OF THE INVENTION

In the search for new MPACs, more effective and safer for patients, a hydrazone derived from the mycobactericidal agent isoniazid was produced, characterized in its crystalline form and successfully tested in modulating in vitro the interaction between β-amyloid peptide (or α-synuclein) and the physiological metals copper and zinc, which can have great impact on the treatment of Alzheimer's and Parkinson's diseases, as well as in other related diseases.

DETAILED DESCRIPTION OF THE INVENTION

The isonicotinoyl hydrazone of 8-hydroxyquinoline-2-carboxaldehyde (or INHHQ) was synthesized, completely characterized in its anhydrous crystalline form and successfully tested in modulating the in vitro interaction between β-amyloid peptide (or α-synuclein) and the physiological metals copper and zinc, which can have applications in the treatment of Alzheimer's and Parkinson's diseases, amongst other neurodegenerative diseases (such as Huntington's).

Structure of INHHQ (8-hydroxyquinoline-2-carboxaldehyde isonicotionoyl hydrazone)

Connected to the 8-hydroxyquinoline portion, characteristic of CQ, INHHQ also contains the mycobactericidal drug isoniazid (INH), resulting in a potentially interesting hydrazone capable of coordinating metal ions of biological importance through its various N/O-donor sites. Furthermore, linking two molecules that have, individually, specific activity, creating a single species, has been an attractive approach to rational drug development, since a combination of the two original activities can be expected of the hybrid molecule. Besides, isoniazid-derived hydrazones are well known as iron chelating agents. However, to the best of our knowledge, there are no studies in the literature involving the coordination of INHHQ to any transition metal.

In the context of the treatment of AD and Parkinson's disease, the coordination capacity of the ligand to essential transition metals (such as copper, zinc and iron) must be better understood. As a first approach to this problem, we present the results of a spectroscopic vibrational (FTIR/Raman) and a single-crystal X-ray diffraction structural study on the 8-hydroxyquinoline-2-carboxaldehyde isonicotinoyl hydrazone, obtained through the process herein described and claimed, including its crystal structure, vibrational spectra and their full assignment by computational methods based on the Density Functional Theory (DFT).

Preparation Methodology of the Anhydrous Crystalline Form of 8-hydroxyquinoline-2-carboxaldehyde isonicotinoyl hydrazone

To 25 mL of a 8-hydroxyquinoline-2-carboxaldehyde (1.04 g, 6.0 mmol) solution in ethanol, 25 mL of ethanolic solution of isoniazid (0.82 g, 6.0 mmol) were dropwise added. Two drops of concentrated hydrochloric acid were added as a catalyst for the reaction. After refluxing for 1 h, the mixture was cooled to room temperature and the yellow precipitate obtained was filtered and vacuum dried. Next, the product was recrystallized in hot methanol methanol PA ACS (99.8%). A pale yellow crystalline solid was obtained after cooling and dried at room temperature. After few days, single-crystals of INHHQ were isolated from the mother liquor. Total yield of the process: 0.98 g (56%).

Characterization:

m.p.: 246-249° C.

Elemental analysis: calculated for C₁₆H₁₂O₂N₄: C, 65.7%; H, 4.1%; N, 19.2%—found: C, 66.3%; H, 4.1%; N, 19.4%.

Main IR bands (KBr, cm⁻¹): 3396 (v OH); 3183 (v NH); 1656 (v C═O+β NH); 1647 (v C═N azomethine group); 1556 (v C═N e v C═C from the quinolinic ring) and 1545 (v C═C e v C═N from the pyridinic ring).

X-Ray Diffraction Analysis

The X-ray diffraction (XRD) was performed using an appropriate single-crystal of INHHQ. The sample was measured on a diffractometer Enraf-Nonius Kappa-CCD with Mo K_α (λ=0.71073 Å) radiation. The unit cell parameters were based on all reflections. Data were collected at room temperature (293 K) using the computer program Collect being the integration and scaling of reflections made with Denzo-Scalepach system of HKL programs. The crystal structure was solved by direct method with SHELXS-97 and the atoms, except hydrogens, were anisotropically refined by the least squares method on F2 using the SHELXL-97 program. All aromatic and hydroxyl group's hydrogen atoms were placed in the calculated positions (C—H: 0.98 Å, O—H: 0.82 Å). Shift factors were taken as U(H)_isot=1.2/1.5 Uhost. The H atoms attached to the C7 carbon and N2 nitrogen were located in the Fourier difference map and refined freely. The computer programs ORTEP-3 and Mercury (version 2.3) were used to draw the structures. On the other hand, powder X-ray diffraction experiments were performed in a Bruker D8 Discover XRD equipment using copper radiation. Experimental conditions: tension of 40 kV and current of 40 mA. The Bragg-Brentano geometry was used.

Spectroscopic Analyses

IR spectra were obtained on a Perkin-Elmer 2000 FT-IR spectrometer, using KBr sampling. On the other hand, the Raman spectra of the solid sample were measured on a Perkin-Elmer 400 Station equipment, using the 785 nm line for excitation.

DFT Calculations

The first step was to conduct a search of the conformational space of 8-hydroxyquinoline-2-carboxaldehyde isonicotinoyl hydrazone using the semi-empirical PM3 method, as implemented in the SPARTAN'02 software, with the following set of parameters: Max-Confs=100; window=10 kcal mol⁻¹; model=PM3. A total of 12 different conformations were found. The lowest energy conformation was of 41.387 kcal mol⁻¹. From this distribution, 5 conformations were selected for analysis by DFT. These conformations will be called, from now on, from Conf. 1 to Conf. 5.

After the selection of these five conformations, a complete geometry optimization, without limitation, using the default convergence criteria and calculation of harmonic vibrational frequencies, was performed in gas phase, for each, using the Gaussian program package 03 Gauss. The three parameters of the exchange-correlation potential proposed by Becke with local and non-local correlations provided by Lee, Yang, and Parr (B3LYP functional) were selected with the basis set of triple zeta valence 6-311+G (d,p). Thermal contributions to the Gibbs free energy and other state functions were calculated at 298.15 K and 1 atm. The vibrational frequencies were scaled by a factor of 0.9381 for a better comparison with the experimental data.

Molecular Structure

Crystallographic Analysis

The main crystal parameters used, as well as data of information collected and structural refinement parameters are summarized in Table 1. INHHQ crystallizes in the orthorhombic system, space group Pbca. The asymmetric unit of INHHQ is shown in FIG. 1. The compound adopts an (E) configuration with respect to the C7=N3 bond of the hydrazonic group. The INHHQ molecule is almost planarin solid state (rms deviation=0.2701° for all atoms, except H) and shows an intramolecular H bond involving the phenolic hydroxyl and the quinolinic nitrogen group: the O1-H donor interacts with N4 [O1 . . . N4=2,689 Å] receptor. In this process, a pseudo five-membered ring is formed. The distances and bond angles (Table 2) are not significantly different from those observed in similar compounds. The crystal packing is maintained by intermolecular H bonds involving the carbonyl oxygen O2 (acceptor) of a molecule and the N2-H group of the following molecule [moderate N2 . . . O2ⁱ=2,966 Å, symmetry codes: (i) −x+½, y−½, z], connecting the molecules of INHHQ in zigzag chains running parallel to the crystallographic b axis (FIG. 2a ). The molecules in each chain are interconnected by cross-stacking π-π interactions involving the quinoline rings. The calculated centroid-centroid distance is equal to 3.8303(9) Å. The adjacent chains are interconnected by O1-H12 . . . π interactions (FIG. 2b ), being the distance H12-centroid (N4-C8-C9-C10-C11-C12) of 3.5339(17) Å [symmetry code: −½+x, y, ½−z]. As a result of this last interaction, zigzag columns run parallel to the crystallographic axis a (FIG. 2c ).

TABLE 1

Selected crystallographic data for INHHQ

Empirical formula	C₁₆H₁₂O₂N₄
Molecular weight	292.30
Collecting temperature	293(2) K
Wave length	0.71073 Å
Crystalline system	Orthorhombic
Space group	Pbca
Unit cell dimensions	a = 17.0761(4) Å
	b = 8.25480(10) Å
	c = 19.3549(4) Å
Cell volume	2728.26(9) Å³
Z	8
ρ(calculated)	1.423 g cm⁻³
Absorption coefficient	0.098 mm⁻¹
F(000)	1216
Crystal size utilized	0.484 × 0.236 × 0.171 mm³
θ range used in collect	2.94 a 27.48°
Index ranges	−22.19; −10.10; −25.23
Collected reflections	27142
Unique	3100 [R_(int)= 0.1167]
Completeness to θ = 27.48°	99.0%
Absorption correction	None
Refinement method	“Full-matrix least-squares on F²”
Computational programs ^a	COLLECT, HKL Denzo and Scalepack,
	SHELXS-97, SHELXL-97
Data/restraints/parameters	3100/0/208
Goodness-of-fit on F²	1.042
Final Rindexes [I > 2σ (I)]	R₁= 0.0517, wR₂= 0.1188
R index (all data)	R₁= 0.0968, wR₂= 0.1427
Largest diff. peak and hole	0.198 and −0.234 e Å⁻³

^aUsed for data collection, data processing, structure solution, and structure refinement, respectively.

TABLE 2

Main distances and bond angles, experimental and theoretical (Conf. 5), for
INHHQ. The crystallographic identification scheme of the atoms was followed

Distances (Å)	Experimental	Calculated	Distances (Å)	Experimental	Calculated

O2—C6	1.2268(18)	1.211	N4—C12	1.362(2)	1.355
N2—C6	1.345(2)	1.388	N3—C7	1.270(2)	1.280
N2—N3	1.3862(18)	1.353	O1—C13	1.358(2)	1.351
N4—C8	1.319(2)	1.325	N1—C1	1.333(2)	1.335

Angles (°)			Angles (°)

C6—N2—N3	118.44(13)	120.9	N2—C6—C5	115.04(13)	114.0
C8—N4—C12	117.83(13)	118.6	C1—N1—C2	116.20(15)	117.2
C7—N3—N2	115.54(13)	117.4	O1—C13—C12	118.65(15)	118.8

Dihedral angles (°)			Dihedral angles (°)

C8—C7—N3—N2	−177.63	179.7	N3—N2—C6—C5	−178.62	−178.6
C7—N3—N2—C6	−163.79	−175.4	N2—C6—C5—C3	144.93	−151.6

Moreover, an analysis of the INHHQ diffraction peaks was performed using Bragg-Brentano geometry (Table 3). The ultimate goal is to characterize, unambiguously, the obtained polymorph. The crystal structure-based simulated diffractogram in the range of 5<2θ<70°, was also calculated. FIG. 3 displays the superposition of the experimental (red) and simulated (blue) diffractograms.

TABLE 3

Information on the diffraction peaks of INHHQ for 2θranging
from 10.5 to 70.5°

Interplanar

Structure

Plane (h, k, l)

Multiplicity

distance (Å)

2 theta

factor

h	k	l	m	d	(°)	F²

1	0	0	2	8.34877	10.58783	1128.338
0	1	0	2	7.07920	12.49361	331.562
0	1	1	4	5.94931	14.87873	4309.398
1	0	−2	2	5.93863	14.90564	3564.964
1	−1	−1	4	5.50433	16.08920	1058.563
0	0	2	2	5.48852	16.13588	185.920
1	1	0	4	5.39942	16.40394	3734.208
1	−1	−2	4	4.54974	19.49495	3562.456
1	1	1	4	4.37713	20.27167	81.922
2	0	−2	2	4.37659	20.27421	2544.993
0	1	2	4	4.33757	20.45853	131.263
2	0	0	2	4.17439	21.26742	743.827
2	−1	−1	4	3.87923	22.90666	5227.304
1	0	2	2	3.87110	22.95541	2615.373
2	−1	−2	4	3.72262	23.88427	1558.836
2	1	0	4	3.59579	24.73979	177.345
0	2	0	2	3.53960	25.13890	1609.181
1	−1	−3	4	3.53090	25.20189	4821.653
1	1	2	4	3.39646	26.21681	4682.200
0	2	1	4	3.36879	26.43604	783.016
1	−2	−1	4	3.28146	27.15290	1838.082
1	2	0	4	3.25881	27.34522	1594.341
2	−1	−3	4	3.25355	27.39035	1187.558
0	1	3	4	3.25049	27.41659	1027.571
3	0	−2	2	3.08971	28.87348	81.686
2	1	1	4	3.08859	28.88417	2178.500
1	−2	−2	4	3.04049	29.35123	126085.008
1	0	−4	2	3.03231	29.43221	46210.547
1	2	1	4	2.98732	29.88574	3959.848
0	2	2	4	2.97465	30.01599	23814.010
2	0	−4	2	2.96931	30.07124	20257.656
3	−1	−2	4	2.83175	31.56923	1316.031
2	−2	−1	4	2.81367	31.77739	2147.033
3	−1	−1	4	2.78865	32.07025	962.328
1	−1	−4	4	2.78737	32.08534	5017.017
2	0	2	2	2.78466	32.11737	5954.872
3	0	0	2	2.78292	32.13796	198029.766
2	−2	−2	4	2.75217	32.50702	166846.703
0	0	4	2	2.74426	32.60332	78569.977
2	−1	−4	4	2.73820	32.67747	7683.784
2	2	0	4	2.69971	33.15667	5524.309
3	−1	−3	4	2.69759	33.18355	5725.885
1	1	3	4	2.69411	33.22766	3144.983
1	−2	−3	4	2.67192	33.51166	5080.103
1	2	2	4	2.61222	34.30092	184684.922
3	0	−4	2	2.61018	34.32857	75081.414
2	1	2	4	2.59139	34.58541	10269.332
3	1	0	4	2.58999	34.60470	3123.402
0	1	4	4	2.55873	35.04100	3632.206
2	−2	−3	4	2.54551	35.22898	128.840
0	2	3	4	2.54404	35.24991	2518.650
2	2	1	4	2.46414	36.43237	9364.604
3	−1	−4	4	2.44902	36.66531	6171.995
0	3	0	2	2.35973	38.10499	2742.504
3	−2	−2	4	2.32767	38.65065	49774.492
1	0	4	2	2.32176	38.75283	27728.582
4	0	−2	2	2.31874	38.80530	8126.180
3	1	1	4	2.31772	38.82317	7422.130
0	3	1	4	2.30703	39.01032	1802.321
3	−2	−1	4	2.30355	39.07167	4033.272
1	−2	−4	4	2.30283	39.08438	4588.360
2	−1	−5	4	2.30097	39.11728	4454.373
1	−3	−1	4	2.27839	39.52090	11520.123
2	−2	−4	4	2.27487	39.58469	7746.600
1	−1	−5	4	2.27151	39.64563	598.446
1	3	0	4	2.27077	39.65907	2802.268
3	−2	−3	4	2.25142	40.01449	3656.189
1	2	3	4	2.24939	40.05204	2882.448
1	1	4	4	2.20614	40.87197	4367.143
4	−1	−2	4	2.20355	40.92216	1606.162
1	−3	−2	4	2.19295	41.12888	5896.017
2	2	2	4	2.18856	41.21509	90978.344
4	0	−4	2	2.18829	41.22042	43250.957
3	2	0	4	2.18772	41.23171	13279.063
4	−1	−3	4	2.18705	41.24487	37423.781
2	1	3	4	2.18427	41.29979	20309.209
1	3	1	4	2.17275	41.52890	27249.758
0	2	4	4	2.16879	41.60831	20608.090
3	−1	−5	4	2.16859	41.61228	15481.041
0	3	2	4	2.16786	41.62688	3233.373
4	−1	−1	4	2.13480	42.30230	2642.791
3	0	2	2	2.13258	42.34844	20.261
2	−3	−1	4	2.10312	42.97079	2666.499
3	−2	−4	4	2.10076	43.02150	1828.689
0	1	5	4	2.09689	43.10495	17605.400
4	−1	−4	4	2.09069	43.23919	2405.904
4	0	0	2	2.08719	43.31522	1974.789
2	−3	−2	4	2.07706	43.53728	2901.627
2	3	0	4	2.05423	44.04625	3037.751
3	1	2	4	2.04194	44.32549	1874.683
1	−3	−3	4	2.04191	44.32613	1474.088
2	0	−6	2	2.03690	44.44102	2853.471
3	2	1	4	2.01612	44.92393	1408.763
1	3	2	4	2.01489	44.95273	793.879
2	−2	−5	4	2.00506	45.18528	8021.569
4	1	0	4	2.00199	45.25840	3930.259
1	−2	−5	4	1.98548	45.65592	1014.055
2	−3	−3	4	1.98380	45.69690	16302.775
0	3	3	4	1.98310	45.71378	11086.845
3	0	−6	2	1.97954	45.80066	5989.497
1	0	−6	2	1.97817	45.83434	9677.354
2	−1	−6	4	1.95748	46.34679	2033.378
2	3	1	4	1.94455	46.67316	3814.112
4	−1	−5	4	1.94222	46.73259	2465.540
1	2	4	4	1.94138	46.75385	1044.347
4	−2	−2	4	1.93962	46.79894	71647.414
2	0	4	2	1.93555	46.90307	22593.117
4	−2	−3	4	1.92834	47.08917	2359.305
2	2	3	4	1.92643	47.13862	3496.081
3	−2	−5	4	1.91564	47.42022	3565.626
3	−1	−6	4	1.90641	47.66401	3852.061
1	−1	−6	4	1.90518	47.69668	126.165
4	−2	−1	4	1.89223	48.04363	2471.013
3	−3	−2	4	1.87535	48.50388	728.923
2	1	4	4	1.86703	48.73407	2582.125
0	2	5	4	1.86568	48.77150	687.112
3	−3	−1	4	1.86266	48.85561	371.683
1	−3	−4	4	1.86228	48.86626	3642.781
4	−2	−4	4	1.86131	48.89351	961.915
1	1	5	4	1.85776	48.99309	2897.553
2	−3	−4	4	1.84740	49.28595	2366.935
5	0	−2	2	1.83827	49.54725	191.546
4	1	1	4	1.83748	49.56990	893.848
3	−3	−3	4	1.83478	49.64793	34517.039
1	3	3	4	1.83368	49.67962	3586.474
4	0	−6	2	1.83168	49.73747	1341.276
0	0	6	2	1.82951	49.80075	5427.721
5	0	−4	2	1.82704	49.87241	2611.138
3	2	2	4	1.82666	49.88361	15035.101
2	3	2	4	1.80028	50.66584	852.734
3	3	0	4	1.79981	50.68000	7635.262
4	2	0	4	1.79790	50.73774	31.252
5	−1	−3	4	1.79778	50.74113	3492.466
3	1	3	4	1.79572	50.80350	1004.864
0	3	4	4	1.78922	51.00132	203.157
5	−1	−2	4	1.77926	51.30747	668.832
4	−1	−6	4	1.77329	51.49295	1637.459
0	1	6	4	1.77131	51.55465	738.791
0	4	0	2	1.76980	51.60187	118322.898
5	−1	−4	4	1.76908	51.62454	2002.556
2	−2	−6	4	1.76545	51.73845	267467.688
4	−2	−5	4	1.75423	52.09423	1767.949
3	−3	−4	4	1.75045	52.21513	447.095
0	4	1	4	1.74724	52.31836	2620.549
1	−4	−1	4	1.73470	52.72556	2457.296
1	4	0	4	1.73133	52.83614	1390.317
3	−2	−6	4	1.72771	52.95534	624.514
1	−2	−6	4	1.72680	52.98560	2870.138
5	−1	−1	4	1.71763	53.29042	3992.833
4	0	2	2	1.71625	53.33669	171.427
3	3	1	4	1.70057	53.86813	4463.794
5	−1	−5	4	1.69944	53.90672	1663.483
2	2	4	4	1.69823	53.94829	3506.858
1	−4	−2	4	1.69608	54.02211	2307.989
2	−3	−5	4	1.69392	54.09682	2349.578
1	2	5	4	1.69125	54.18921	1409.942
2	−1	−7	4	1.69108	54.19489	787.935
1	4	1	4	1.68669	54.34788	882.257
0	4	2	4	1.68440	54.42786	182.510
1	−3	−5	4	1.68206	54.50961	4158.873
3	−1	−7	4	1.68013	54.57753	2978.968
4	2	1	4	1.67591	54.72649	1026.918
5	0	0	2	1.66975	54.94516	2190.528
4	1	2	4	1.66794	55.01012	1131.238
1	3	4	4	1.65500	55.47716	297.480
4	−3	−2	4	1.65390	55.51703	92.102
2	−4	−1	4	1.65348	55.53225	2628.066
4	−3	−3	4	1.64689	55.77391	1703.457
2	3	3	4	1.64570	55.81771	14933.787
5	−2	−3	4	1.64562	55.82063	904.931
5	0	−6	2	1.64485	55.84915	11045.036
3	2	3	4	1.64404	55.87900	537.543
1	0	6	2	1.64248	55.93667	4104.017
2	−4	−2	4	1.64073	56.00177	6555.738
3	−3	−5	4	1.63896	56.06742	3117.231
1	−1	−7	4	1.63562	56.19224	7479.478
5	−2	−2	4	1.63138	56.35117	139974.406
2	4	0	4	1.62941	56.42557	2336.839
3	0	4	2	1.62858	56.45687	79060.617
4	−2	−6	4	1.62677	56.52512	231.031
0	2	6	4	1.62525	56.58301	200.360
5	1	0	4	1.62516	56.58630	1372.377
4	−3	−1	4	1.62423	56.62165	941.537
5	−2	−4	4	1.62352	56.64860	977.446
1	−4	−3	4	1.62324	56.65939	3828.351
2	1	5	4	1.62060	56.76011	661.635
1	4	2	4	1.60956	57.18482	2848.325
0	3	5	4	1.60734	57.27112	4687.052
4	−1	−7	4	1.60639	57.30817	785.019
4	−3	−4	4	1.60455	57.38024	979.594
5	−1	−6	4	1.60217	57.47322	229.132
1	1	6	4	1.59998	57.55912	756.968
2	−4	−3	4	1.59358	57.81228	6432.516
0	4	3	4	1.59322	57.82655	993.033
3	1	4	4	1.58712	58.06987	1480.846
5	−2	−1	4	1.58349	58.21592	1232.501
3	3	2	4	1.58219	58.26825	878.980
2	4	1	4	1.57302	58.64091	2737.882
5	−2	−5	4	1.56920	58.79766	1757.640
4	3	0	4	1.56339	59.03785	1224.589
2	−2	−7	4	1.56261	59.07000	858.527
3	−2	−7	4	1.55396	59.43196	388.934
6	0	−4	2	1.54485	59.81773	40226.578
4	2	2	4	1.54429	59.84161	132527.313
2	−3	−6	4	1.54191	59.94356	919.952
3	−4	−2	4	1.53571	60.21080	3337.484
4	−3	−5	4	1.53442	60.26657	2142.301
0	1	7	4	1.53103	60.41363	4066.389
3	−4	−1	4	1.52872	60.51473	530.741
1	−4	−4	4	1.52851	60.52394	23281.965
3	0	−8	2	1.52498	60.67867	13248.033
2	−4	−4	4	1.52025	60.88755	1880.706
1	−2	−7	4	1.51854	60.96338	1753.461
6	0	−2	2	1.51698	61.03271	2012.546
3	−3	−6	4	1.51658	61.05053	1466.016
5	1	1	4	1.51638	61.05931	161.170
2	0	−8	2	1.51616	61.06934	3710.299
1	−3	−6	4	1.51596	61.07813	2665.123
3	−4	−3	4	1.51319	61.20197	419.151
1	4	3	4	1.51257	61.22953	10115.472
6	−1	−3	4	1.51024	61.33418	363.616
5	2	0	4	1.51016	61.33806	617.463
6	−1	−4	4	1.50933	61.37515	989.558
4	1	3	4	1.50872	61.40297	297.840
2	2	5	4	1.50649	61.50344	588.937
2	3	4	4	1.49652	61.95818	590.113
4	−2	−7	4	1.49506	62.02536	423.413
2	4	2	4	1.49366	62.09007	106.506
3	4	0	4	1.49339	62.10246	123565.250
1	3	5	4	1.49174	62.17898	478.546
5	−2	−6	4	1.49166	62.18267	105324.078
5	−1	−7	4	1.49157	62.18692	1581.715
3	−1	−8	4	1.49078	62.22328	974.226
1	2	6	4	1.48989	62.26457	134633.219
0	4	4	4	1.48733	62.38401	83526.117
4	0	−8	2	1.48466	62.50882	50996.125
6	−1	−2	4	1.48331	62.57221	539.855
2	−1	−8	4	1.48254	62.60831	1032.783
4	3	1	4	1.48118	62.67218	6016.078
6	−1	−5	4	1.48072	62.69367	7655.220
3	2	4	4	1.47949	62.75186	5174.257
3	−4	−4	4	1.46483	63.45251	92852.609
1	0	−8	2	1.46062	63.65703	34382.762
5	−3	−3	4	1.46015	63.67986	19231.883
3	3	3	4	1.45904	63.73375	2083.547
6	0	−6	2	1.45886	63.74255	104.403
2	0	6	2	1.45666	63.85023	5589.541
4	−1	−8	4	1.45305	64.02798	501.111
5	−3	−2	4	1.45017	64.17003	1181.973
4	−3	−6	4	1.44693	64.33096	2199.269
0	3	6	4	1.44586	64.38455	3392.815
5	−3	−4	4	1.44464	64.44527	603.990
3	4	1	4	1.43522	64.91979	856.294
0	2	7	4	1.43374	64.99512	3941.112
6	−1	−1	4	1.43271	65.04772	9958.013
5	0	2	2	1.43178	65.09530	464.878
2	−4	−5	4	1.43122	65.12385	1343.613
1	−1	−8	4	1.43049	65.16140	2849.458
6	−1	−6	4	1.42884	65.24586	1632.203
2	1	6	4	1.42677	65.35220	113.830
1	−4	−5	4	1.42405	65.49281	2715.529
5	2	1	4	1.42169	65.61510	2686.276
6	−2	−3	4	1.41663	65.87928	845.347
5	−3	−1	4	1.41622	65.90063	1809.560
6	−2	−4	4	1.41588	65.91867	654.705
0	5	0	2	1.41584	65.92052	1197.549
4	2	3	4	1.41537	65.94542	244.526
3	1	5	4	1.41356	66.04055	4426.744
1	4	4	4	1.40751	66.36081	21200.830
4	−4	−2	4	1.40684	66.39668	396.245
5	−3	−5	4	1.40597	66.44291	29.975
5	0	−8	2	1.40574	66.45520	3142.987
0	5	1	4	1.40421	66.53712	7893.484
5	1	2	4	1.40336	66.58237	970.894
1	1	7	4	1.40288	66.60856	170.244
4	−4	−3	4	1.40251	66.62790	1310.150
2	4	3	4	1.40178	66.66737	2531.638
2	−3	−7	4	1.40123	66.69715	8505.064
5	−2	−7	4	1.40118	66.69978	401.337
3	−2	−8	4	1.40053	66.73479	5147.162
1	−5	−1	4	1.39767	66.88894	1543.957
3	−4	−5	4	1.39761	66.89248	1963.978
1	5	0	4	1.39591	66.98464	1123.055
3	−3	−7	4	1.39498	67.03543	1584.166
6	−2	−2	4	1.39432	67.07096	6423.831
2	−2	−8	4	1.39368	67.10576	2221.480
4	0	4	2	1.39233	67.17963	9756.798
6	−2	−5	4	1.39218	67.18803	123.361
6	0	0	2	1.39146	67.22715	61458.719
4	−4	−1	4	1.38844	67.39312	1208.544
4	3	2	4	1.38797	67.41877	146.200
5	−1	−8	4	1.37882	67.92709	1203.279
0	4	5	4	1.37785	67.98154	710.651
1	−5	−2	4	1.37724	68.01559	3062.095
4	−4	−4	4	1.37608	68.08057	27359.787
1	5	1	4	1.37219	68.30019	694.557
0	0	8	2	1.37213	68.30382	15200.482
0	5	2	4	1.37096	68.37016	828.054
1	−3	−7	4	1.36918	68.47118	3214.390
4	−2	−8	4	1.36910	68.47589	45.553
4	1	4	4	1.36616	68.64389	519.685
6	1	0	4	1.36534	68.69093	1607.419
5	3	0	4	1.36303	68.82355	2112.606
3	4	2	4	1.36190	68.88850	1753.492
6	−1	−7	4	1.36065	68.96085	2649.621
2	3	5	4	1.36033	68.97921	2510.422
2	−5	−1	4	1.35414	69.33989	3657.629
6	−2	−1	4	1.35205	69.46230	243.801
4	−3	−7	4	1.35190	69.47100	6915.945
1	−2	−8	4	1.35018	69.57237	1099.760
4	4	0	4	1.34986	69.59140	705.399
5	−3	−6	4	1.34938	69.61938	756.755
6	−2	−6	4	1.34879	69.65417	2227.248
1	3	6	4	1.34807	69.69667	318.911
2	−5	−2	4	1.34710	69.75419	61.678
0	1	8	4	1.34706	69.75684	1471.690
2	2	6	4	1.34705	69.75717	576.139
2	5	0	4	1.34082	70.12915	2349.962
3	3	4	4	1.34035	70.15689	35.647
1	−5	−3	4	1.33737	70.33644	2229.274
2	−4	−6	4	1.33596	70.42175	3337.051
3	2	5	4	1.33592	70.42439	156.499

Gas-Phase DFT Calculations

The INHHQ structure was optimized in gas phase, using the DFT methodology, level of theory B3LYP/6-311+G (d,p).

As described above, a total of 5 conformations with the smallest PM3 energy differences were selected to perform a DFT optimization and frequency calculations. Cis-trans isomerism was contemplated in this treatment. Energy values found for each of these structures indicated that there are, in fact, only 3 different conformations. Conf. 5 is the one with the lowest free energy (ΔG) when compared to the other conformations. However, the energy differences between the structures are not appreciable, especially between the Conf. 1/2 with respect to the Conf. 5 (only 0.06 kcal mol⁻¹), indicating that, indeed, all five conformations are possible, particularly Conf. 5. This last one was chosen for further deeper studies.

It is shown (Table 2) that there is excellent agreement between the structural parameters found in the calculations (Conf. 5) and the refined X-ray structure and that, in turn, there is no significant difference between FIGS. 1 and 4. Crystallography shows that the phenolic hydrogen points in the direction of the quinolinic nitrogen, since a connection involving these H atoms is formed, producing a 2.691 Å donor-acceptor distance, in perfect agreement with the X-ray data (O1 . . . N4=2.689 Å).

Vibrational Analyses

The experimental FTIR and Raman spectra of INHHQ, in the solid state, are shown in FIG. 5. The observed and calculated frequencies, as well as an attempt to assign the main bands, are given in Table 4.

TABLE 4

Assignment of the FTIR and Raman spectra of INHHQ (scale factor: 0.9381)

	Theoretical (cm⁻¹)
	B3LYP/6-311 + G(d, p)

Experimental (cm⁻¹)	Unscaled	Scaled
FTIRRaman	(cm⁻¹)	(cm⁻¹)	IR Intensity	Vibrational Assignment

3396	m	3400	br	3662	3435	104.3584	v OH
3208	sh	3205	w				—

3183	w	—	3502	3285	5.5099	v NH
3148	sh	—	3211/3205	3012/3007	1.8906/3.2991	v CH(Quin + Py)ip

3073	sh	3081	w	3198	3000	9.2441	v CH(Quin)ip
3059	sh	3055	w	3185/3178	2988/2981	18.7464/9.9528	v CH(Quin + Py)op

3042

w

—

3028

sh

3030

w

—

3016

w

—

2996

w

—

2959	sh	—				—
2923	w	—				—
2852	w	—	3048	2859	40.4835	vCH(Azomethine)
2835	sh	—				—

1656	s	1660	sh	1767	1658	350.6350	vC═O + βNH
1647	vs	1646	w	1673	1569	20.7477	v C═N(Azomethine) +
							v C═C(Quin) + βC—OH
1604	w	1603	vs	1659	1556	2.3397	v C═N(Azomethine) +
							v C═C(Quin) + βC—OH
1595	w	1595	s	1634	1533	5.5690	v C═C(Quin)
1556	m	1555	w	1597	1498	18.4149	v C═N(Quin) + vC═C(Quin)

1545

m

—

1630

1529

14.2312

v C═C(Py) + vC═N(Py)

1507	m	1507	w	1555	1459	371.3416	βNH + βCH(Quin)
1490	w	1488	vw				—
1465	m	1468	w	1541	1446	168.8474	Ring stretch(Quin) +
							βC—OH + β NH
1437	m	1435	s	1519	1425	6.8860	βCH(Py)

1407

w

—

1394	sh	1396	m				—
1371	w	1371	m	1495	1402	176.2051	β C—OH + β NH +
							β CH(Quin)
1330	m	1329	m				—
1299	s	1304	m	1360	1276	34.4059	β CH(Quin + Azomethine) +
							v C═N(Quin) + v C—OH
1280	m	1279	sh	1347	1264	31.7632	β NH + β
							CH(Azomethine + Py) +
							β C—OH

1270

sh

—

1252	m	1252	s	1309	1228	15.0576	β CH(Quin +
							Azomethyne) + β C—OH

1232	m	—	1284	1205	117.6910	v C—OH + β CH(Quin +
						Azomethine)

1217	w	1220	w	1278	1199	32.0853	v C═N(Py) + vC═C(Py) +
							β NH
1204	w	1204	vw	1267	1189	56.8637	β CH(Azomethine +
							Quin) + β C—OH
1170	w	1172	sh	1253	1175	303.5474	βCH(Py) + βNH
1156	m	1156	m	1172	1099	380.9402	v N—N + βCH(Py +
							Quin)
1136	w	1133	w	1112	1043	10.8679	βCH(Py)

1122

sh

—

1105	w	1105	vw				—
1090	w	1093	vw	1109	1040	19.7634	βCH(Py + Quin)
1072	w	1076	w	1092	1024	9.3109	βCH(Py)

—

1063

vw

1079

1012

11.9293

βCH(Quin) + δ NNC

1044

vw

1044

vw

1068

1002

1.6514

βCH(Quin)

1007

vw

—

992

vw

992

w

1010

947

1.7715

Ring breath(Py)

981

vw

—

1008

946

1.5921

γCH(Py)

950	vw	952	w	959	900	14.8080	γCH(Azomethine)
931	w	932	w	914	857	2.9777	Ring-deformation(Quin +
							Py)
895	w	897	vw				—

881

vw

—

867	w	869	w	898	842	0.0665	γCH(Quin)
856	m	855	sh	880	826	11.8041	Ring-deformation(Quin +
							Py)
837	m	835	vw	892	837	2.8606	γCH(Py)

—	812	vw	804	754	2.0048	γ C═C—C(Quin) +
						γ C═N—C(Quin)

792	vw	780	w	789	740	5.7350	β C═C—C(Quin +
							Azomethine)
766	s	768	vw	767	720	9.2858	γCH(Py)
720	m	720	m	734	689	18.7702	Ring-deformation(Quin)
696	w	696	vw	763	716	38.2602	γ CH(Quin)

677	s	—	719	674	19.3631	β C═N—C(Py) +
						β C═C—C(Quin)

670	sh	668	w	698	655	2.0785	γ C═C—C(Quin) +
							β C═N—C(Py)
656	w	657	w	693	650	58.0279	Ring-deformation(Py)

644	sh	—	681	639	1.5003	Ring-deformation(Py)
616	vw	—	627	588	2.3638	Ring-deformation(Quin)
587	m	—	604	567	90.9456	γ OH
575	w	—				—

547	sh	553	w	588	552	10.5255	β C═C—C(Quin)
532	sh	533	vw	559	524	1.6705	β C═C—C(Quin) + γ NH
522	w	523	vw	551	517	14.1393	γCH(Quin) +
							β C═C—C(Quin) +
							β C—OH
482	w	485	w	539/534	506/501	16.0281/30.1104	γ NH + γ C═C—C(Quin)

Quin: quinoline ring; Py: pyridine ring; vs: very strong; s: strong; m: medium; w: weak; vw: very weak; br: broad; sh: shoulder; ip: in-phase; op: out-of-phase; v: stretching; β: in-plane bending; γ: out-of-plane bending.

Carbonylic C═O Stretching

The v C═O absorption is usually one of the most representative in an infrared spectrum and is also likely its most intense spectral feature. It appears in a wavenumber region relatively free of other vibrations (1800-1600 cm⁻¹). On the other hand, this mode gives only weak or very weak absorptions in Raman spectroscopy. In our study, as expected, v C═O vibration originates one of the strongest bands of the infrared spectrum, at 1656 cm⁻¹, which is in excellent agreement with the calculated value of 1658 cm⁻¹(DFT calculations show a coupling between v C═O and β NH vibrations).

This mode was assigned at 1663 cm⁻¹by Liu and Yang.

Azomethine C═N Stretching

The C═N stretchings of azomethine groups show absorptions close to that of carbonyl stretching. This fact can difficult an accurate assignment. For example, the C═N stretching bands of alkylated Schiff bases are usually found in the range 1674-1649 cm⁻¹, inside the common region of v C═O absorption. If conjugations of the C═N moiety with phenyl groups are present, the stretching frequency shifts to 1650-1600 cm⁻¹. In this work, two frequencies involving azomethine C═N vibrations were calculated (1569/1556 cm⁻¹), both of them coupled to v C═C of the quinoline ring and, to a lesser extent, to the phenol v C—OH. These values are in good agreement with the experimental frequencies observed in the infrared, at 1647 (vs) and 1604 (w) cm⁻¹, and Raman spectra, at 1646 (w) and 1603 (vs) cm⁻¹, respectively.

Liu and Yang, though, attributed this mode to a single band at 1613 cm⁻¹in the IR spectrum, which was not observed in our study.

OH and NH Stretching Vibrations

OH and NH groups are very characteristic and their stretching vibrations are observed, in many cases, around 3500-3300 cm⁻¹. This absorption, however, is highly influenced by chemical environment, mainly when OH or NH groups are involved in hydrogen bonding. This can occur within the same molecule (intramolecular H bonding) or with adjacent molecules (intermolecular H bonding). The presence of intramolecular H bonding causes a thinning of the band and makes its position unaffected by concentration changes. In the IR spectrum of INHHQ, we observed a sharp band of medium intensity located at 3396 cm⁻¹, assigned to v OH. A similar absorption, at 3418 cm⁻¹, was reported by Krishnakumar and Ramasamy in the infrared spectrum of 8-hydroxyquinoline (8-HQ). On the other hand, intermolecular hydrogen bonding usually leads to a broadening of the band, as can be seen in the case of the v NH absorption of INHHQ, which was attributed to the weak IR band at 3183 cm⁻¹. In a previous study on the isonicotinoyl hydrazone of 2-hydroxy-3-methoxybenzaldehyde, published by us, v NH vibration was observed as a weak band at 3157 cm⁻¹. Here, we found serious discrepancies concerning the assignments made by Liu and Yang, since these authors attributed an absorption of higher frequency (reported by them at 3576 cm⁻¹) to the NH stretching mode, whereas the lower frequency band at 3193 cm⁻¹was credited to the OH stretching movement.

Phenol C—OH Vibrations

In this work, the C—OH stretching mode was assigned to the medium intensity infrared band at 1232 cm⁻¹. This vibration is Raman inactive and had its frequency calculated at 1205 cm⁻¹. A coupled mode involving this movement was also predicted at 1276 cm⁻¹[experimental: 1299 (infrared) cm⁻¹and 1304 (Raman) cm⁻¹]. Another important vibration concerning the phenol group is the in-plane bending, which typically appears in the region 1440-1260 cm⁻¹, attributed to the weak infrared band (medium in the Raman spectrum) at 1371 cm⁻¹. Coupled modes are observed in FTIR at 1465, 1280, 1252 and 1202 cm⁻¹. Theoretical and experimental frequencies show good agreement (Table 4).

Biological Activity Studies

This hydrazonic compound has the ability, as proved by 1D and 2D NMR experiments, of compete with the β-amyloid peptide (or α-synuclein), key-targets, respectively, in Alzheimer's and Parkinson's diseases, by physiological ions such as Zn²⁺ Cu²⁺ and Cu⁺, which can cause their precipitation or oligomerization and contribute to worsen the oxidative stress condition observed in the brains of patients suffering from these neurodegenerative disorders. INHHQ does not interact directly with the β-amyloid peptide and α-synuclein, nonetheless inhibits the interactions between these targets and metals through a mechanism that probably involves metal ion sequestering.

In silico pharmacological analyses (mandatory studies in the development of new therapeutic agents, whose aim is to predict pharmacokinetic properties of novel molecules with a potential pharmacological action) show that the Lipinski's parameters presented by INHHQ (Table 5), calculated via 1D-QSAR method, are in agreement to ideal values, suggesting that this compound constitutes an excellent candidate to new drug, with good oral absorption and cellular permeability. The model also indicates that INHHQ possesses structural features which can allow it crossing the blood-brain barrier (BBB), resulting in therapeutic actions inside the patients' brains.

TABLE 5

Lipinski parameters calculated for
INHHQ, along with reference values

		Ref. Oral	Ref. BBB
Parameters	INHHQ	Biodisponibility	Crossing

HBD

	2	≤5	≤3
HBA	6	≤10	≤7
MW	292	≤500	≤400
log P	2.34	−1 a 5	−1 a 5
log D (pH = 7.4)	2.27	−1 a 5	−1 a 5
log S	−3.36	−4 a 2	−4 a 2
PSA	66.077 Å	≤140 Å	≤90 Å
Rotatable bonds	4	≤10	≤10

Furthermore, both the INHHQ molecule itself and its potential metabolites were shown, in theoretical comparison with the toxic fragments of over 3000 commercially available drugs, completely non-toxic.

In fact, the intraperitoneal injection of up to 300 mg kg⁻¹of the compound, using 10% DMSO/saline solution as vehicle of injection, in Wistar male rats (acute toxicity test) showed that INHHQ was apparently not toxic to the animals throughout the 72 h of the experiment: no animals died and there were no behavioral changes noted in the injected rats. Also, after the animals' sacrifice, there were no macroscopic abnormalities observed during its organs dissection.

Claims

The invention claimed is:

1. A crystalline polymorph of the anhydrous form, comprising:

I—the crystal structure of FIG. 1:

II—crystal packing comprising one or more of the following features:

(a) maintained by intermolecular H bonds involving the carbonyl oxygen O2 (acceptor) of a molecule and the N2-H group of the following molecule [moderate N2 . . . O2ⁱ=2,966 Å, symmetry codes: (i) −x+½, y−½, z], connecting the molecules of INHHQ in zigzag chains; or

(b) molecules in each chain interconnected by cross-stacking π-π interactions involving the quinoline rings, being the calculated centroid-centroid distance equal to 3.8303(9) Å, and the adjacent chains interconnected by O1-H12 . . . π interactions; or

(c) as a result of the mentioned O1-H12 . . . π interactions, zigzag columns run parallel to the crystallographic axis a; and

III—the following characteristics:

Melting point 246-249° C. Elemental analysis C, 66.3%; H, 4.1%; N, 19.4% Crystal system Orthorhombic Unit cell size a = 17.0761(4) Å b = 8.25480(10) Å c = 19.3549(4) Å Z 8 ρ (calculated) 1.423 g cm⁻³.

2. The crystalline polymorph of the anhydrous form according to claim 1, presenting X-ray diffraction peaks (2θ ranging from 10.5 to 70.5°) as follows:

Interplanar Plane (h, k, l) Multiplicity distance (Å) 2 theta (°) H k l m d 1 0 0 2 8.34877 10.58783 0 1 0 2 7.07920 12.49361 0 1 1 4 5.94931 14.87873 1 0 −2 2 5.93863 14.90564 1 −1 −1 4 5.50433 16.08920 0 0 2 2 5.48852 16.13588 1 1 0 4 5.39942 16.40394 1 −1 −2 4 4.54974 19.49495 1 1 1 4 4.37713 20.27167 2 0 −2 2 4.37659 20.27421 0 1 2 4 4.33757 20.45853 2 0 0 2 4.17439 21.26742 2 −1 −1 4 3.87923 22.90666 1 0 2 2 3.87110 22.95541 2 −1 −2 4 3.72262 23.88427 2 1 0 4 3.59579 24.73979 0 2 0 2 3.53960 25.13890 1 −1 −3 4 3.53090 25.20189 1 1 2 4 3.39646 26.21681 0 2 1 4 3.36879 26.43604 1 −2 −1 4 3.28146 27.15290 1 2 0 4 3.25881 27.34522 2 −1 −3 4 3.25355 27.39035 0 1 3 4 3.25049 27.41659 3 0 −2 2 3.08971 28.87348 2 1 1 4 3.08859 28.88417 1 −2 −2 4 3.04049 29.35123 1 0 −4 2 3.03231 29.43221 1 2 1 4 2.98732 29.88574 0 2 2 4 2.97465 30.01599 2 0 −4 2 2.96931 30.07124 3 −1 −2 4 2.83175 31.56923 2 −2 −1 4 2.81367 31.77739 3 −1 −1 4 2.78865 32.07025 1 −1 −4 4 2.78737 32.08534 2 0 2 2 2.78466 32.11737 3 0 0 2 2.78292 32.13796 2 −2 −2 4 2.75217 32.50702 0 0 4 2 2.74426 32.60332 2 −1 −4 4 2.73820 32.67747 2 2 0 4 2.69971 33.15667 3 −1 −3 4 2.69759 33.18355 1 1 3 4 2.69411 33.22766 1 −2 −3 4 2.67192 33.51166 1 2 2 4 2.61222 34.30092 3 0 −4 2 2.61018 34.32857 2 1 2 4 2.59139 34.58541 3 1 0 4 2.58999 34.60470 0 1 4 4 2.55873 35.04100 2 −2 −3 4 2.54551 35.22898 0 2 3 4 2.54404 35.24991 2 2 1 4 2.46414 36.43237 3 −1 −4 4 2.44902 36.66531 0 3 0 2 2.35973 38.10499 3 −2 −2 4 2.32767 38.65065 1 0 4 2 2.32176 38.75283 4 0 −2 2 2.31874 38.80530 3 1 1 4 2.31772 38.82317 0 3 1 4 2.30703 39.01032 3 −2 −1 4 2.30355 39.07167 1 −2 −4 4 2.30283 39.08438 2 −1 −5 4 2.30097 39.11728 1 −3 −1 4 2.27839 39.52090 2 −2 −4 4 2.27487 39.58469 1 −1 −5 4 2.27151 39.64563 1 3 0 4 2.27077 39.65907 3 −2 −3 4 2.25142 40.01449 1 2 3 4 2.24939 40.05204 1 1 4 4 2.20614 40.87197 4 −1 −2 4 2.20355 40.92216 1 −3 −2 4 2.19295 41.12888 2 2 2 4 2.18856 41.21509 4 0 −4 2 2.18829 41.22042 3 2 0 4 2.18772 41.23171 4 −1 −3 4 2.18705 41.24487 2 1 3 4 2.18427 41.29979 1 3 1 4 2.17275 41.52890 0 2 4 4 2.16879 41.60831 3 −1 −5 4 2.16859 41.61228 0 3 2 4 2.16786 41.62688 4 −1 −1 4 2.13480 42.30230 3 0 2 2 2.13258 42.34844 2 −3 −1 4 2.10312 42.97079 3 −2 −4 4 2.10076 43.02150 0 1 5 4 2.09689 43.10495 4 −1 −4 4 2.09069 43.23919 4 0 0 2 2.08719 43.31522 2 −3 −2 4 2.07706 43.53728 2 3 0 4 2.05423 44.04625 3 1 2 4 2.04194 44.32549 1 −3 −3 4 2.04191 44.32613 2 0 −6 2 2.03690 44.44102 3 2 1 4 2.01612 44.92393 1 3 2 4 2.01489 44.95273 2 −2 −5 4 2.00506 45.18528 4 1 0 4 2.00199 45.25840 1 −2 −5 4 1.98548 45.65592 2 −3 −3 4 1.98380 45.69690 0 3 3 4 1.98310 45.71378 3 0 −6 2 1.97954 45.80066 1 0 −6 2 1.97817 45.83434 2 −1 −6 4 1.95748 46.34679 2 3 1 4 1.94455 46.67316 4 −1 −5 4 1.94222 46.73259 1 2 4 4 1.94138 46.75385 4 −2 −2 4 1.93962 46.79894 2 0 4 2 1.93555 46.90307 4 −2 −3 4 1.92834 47.08917 2 2 3 4 1.92643 47.13862 3 −2 −5 4 1.91564 47.42022 3 −1 −6 4 1.90641 47.66401 1 −1 −6 4 1.90518 47.69668 4 −2 −1 4 1.89223 48.04363 3 −3 −2 4 1.87535 48.50388 2 1 4 4 1.86703 48.73407 0 2 5 4 1.86568 48.77150 3 −3 −1 4 1.86266 48.85561 1 −3 −4 4 1.86228 48.86626 4 −2 −4 4 1.86131 48.89351 1 1 5 4 1.85776 48.99309 2 −3 −4 4 1.84740 49.28595 5 0 −2 2 1.83827 49.54725 4 1 1 4 1.83748 49.56990 3 −3 −3 4 1.83478 49.64793 1 3 3 4 1.83368 49.67962 4 0 −6 2 1.83168 49.73747 0 0 6 2 1.82951 49.80075 5 0 −4 2 1.82704 49.87241 3 2 2 4 1.82666 49.88361 2 3 2 4 1.80028 50.66584 3 3 0 4 1.79981 50.68000 4 2 0 4 1.79790 50.73774 5 −1 −3 4 1.79778 50.74113 3 1 3 4 1.79572 50.80350 0 3 4 4 1.78922 51.00132 5 −1 −2 4 1.77926 51.30747 4 −1 −6 4 1.77329 51.49295 0 1 6 4 1.77131 51.55465 0 4 0 2 1.76980 51.60187 5 −1 −4 4 1.76908 51.62454 2 −2 −6 4 1.76545 51.73845 4 −2 −5 4 1.75423 52.09423 3 −3 −4 4 1.75045 52.21513 0 4 1 4 1.74724 52.31836 1 −4 −1 4 1.73470 52.72556 1 4 0 4 1.73133 52.83614 3 −2 −6 4 1.72771 52.95534 1 −2 −6 4 1.72680 52.98560 5 −1 −1 4 1.71763 53.29042 4 0 2 2 1.71625 53.33669 3 3 1 4 1.70057 53.86813 5 −1 −5 4 1.69944 53.90672 2 2 4 4 1.69823 53.94829 1 −4 −2 4 1.69608 54.02211 2 −3 −5 4 1.69392 54.09682 1 2 5 4 1.69125 54.18921 2 −1 −7 4 1.69108 54.19489 1 4 1 4 1.68669 54.34788 0 4 2 4 1.68440 54.42786 1 −3 −5 4 1.68206 54.50961 3 −1 −7 4 1.68013 54.57753 4 2 1 4 1.67591 54.72649 5 0 0 2 1.66975 54.94516 4 1 2 4 1.66794 55.01012 1 3 4 4 1.65500 55.47716 4 −3 −2 4 1.65390 55.51703 2 −4 −1 4 1.65348 55.53225 4 −3 −3 4 1.64689 55.77391 2 3 3 4 1.64570 55.81771 5 −2 −3 4 1.64562 55.82063 5 0 −6 2 1.64485 55.84915 3 2 3 4 1.64404 55.87900 1 0 6 2 1.64248 55.93667 2 −4 −2 4 1.64073 56.00177 3 −3 −5 4 1.63896 56.06742 1 −1 −7 4 1.63562 56.19224 5 −2 −2 4 1.63138 56.35117 2 4 0 4 1.62941 56.42557 3 0 4 2 1.62858 56.45687 4 −2 −6 4 1.62677 56.52512 0 2 6 4 1.62525 56.58301 5 1 0 4 1.62516 56.58630 4 −3 −1 4 1.62423 56.62165 5 −2 −4 4 1.62352 56.64860 1 −4 −3 4 1.62324 56.65939 2 1 5 4 1.62060 56.76011 1 4 2 4 1.60956 57.18482 0 3 5 4 1.60734 57.27112 4 −1 −7 4 1.60639 57.30817 4 −3 −4 4 1.60455 57.38024 5 −1 −6 4 1.60217 57.47322 1 1 6 4 1.59998 57.55912 2 −4 −3 4 1.59358 57.81228 0 4 3 4 1.59322 57.82655 3 1 4 4 1.58712 58.06987 5 −2 −1 4 1.58349 58.21592 3 3 2 4 1.58219 58.26825 2 4 1 4 1.57302 58.64091 5 −2 −5 4 1.56920 58.79766 4 3 0 4 1.56339 59.03785 2 −2 −7 4 1.56261 59.07000 3 −2 −7 4 1.55396 59.43196 6 0 −4 2 1.54485 59.81773 4 2 2 4 1.54429 59.84161 2 −3 −6 4 1.54191 59.94356 3 −4 −2 4 1.53571 60.21080 4 −3 −5 4 1.53442 60.26657 0 1 7 4 1.53103 60.41363 3 −4 −1 4 1.52872 60.51473 1 −4 −4 4 1.52851 60.52394 3 0 −8 2 1.52498 60.67867 2 −4 −4 4 1.52025 60.88755 1 −2 −7 4 1.51854 60.96338 6 0 −2 2 1.51698 61.03271 3 −3 −6 4 1.51658 61.05053 5 1 1 4 1.51638 61.05931 2 0 −8 2 1.51616 61.06934 1 −3 −6 4 1.51596 61.07813 3 −4 −3 4 1.51319 61.20197 1 4 3 4 1.51257 61.22953 6 −1 −3 4 1.51024 61.33418 5 2 0 4 1.51016 61.33806 6 −1 −4 4 1.50933 61.37515 4 1 3 4 1.50872 61.40297 2 2 5 4 1.50649 61.50344 2 3 4 4 1.49652 61.95818 4 −2 −7 4 1.49506 62.02536 2 4 2 4 1.49366 62.09007 3 4 0 4 1.49339 62.10246 1 3 5 4 1.49174 62.17898 5 −2 −6 4 1.49166 62.18267 5 −1 −7 4 1.49157 62.18692 3 −1 −8 4 1.49078 62.22328 1 2 6 4 1.48989 62.26457 0 4 4 4 1.48733 62.38401 4 0 −8 2 1.48466 62.50882 6 −1 −2 4 1.48331 62.57221 2 −1 −8 4 1.48254 62.60831 4 3 1 4 1.48118 62.67218 6 −1 −5 4 1.48072 62.69367 3 2 4 4 1.47949 62.75186 3 −4 −4 4 1.46483 63.45251 1 0 −8 2 1.46062 63.65703 5 −3 −3 4 1.46015 63.67986 3 3 3 4 1.45904 63.73375 6 0 −6 2 1.45886 63.74255 2 0 6 2 1.45666 63.85023 4 −1 −8 4 1.45305 64.02798 5 −3 −2 4 1.45017 64.17003 4 −3 −6 4 1.44693 64.33096 0 3 6 4 1.44586 64.38455 5 −3 −4 4 1.44464 64.44527 3 4 1 4 1.43522 64.91979 0 2 7 4 1.43374 64.99512 6 −1 −1 4 1.43271 65.04772 5 0 2 2 1.43178 65.09530 2 −4 −5 4 1.43122 65.12385 1 −1 −8 4 1.43049 65.16140 6 −1 −6 4 1.42884 65.24586 2 1 6 4 1.42677 65.35220 1 −4 −5 4 1.42405 65.49281 5 2 1 4 1.42169 65.61510 6 −2 −3 4 1.41663 65.87928 5 −3 −1 4 1.41622 65.90063 6 −2 −4 4 1.41588 65.91867 0 5 0 2 1.41584 65.92052 4 2 3 4 1.41537 65.94542 3 1 5 4 1.41356 66.04055 1 4 4 4 1.40751 66.36081 4 −4 −2 4 1.40684 66.39668 5 −3 −5 4 1.40597 66.44291 5 0 −8 2 1.40574 66.45520 0 5 1 4 1.40421 66.53712 5 1 2 4 1.40336 66.58237 1 1 7 4 1.40288 66.60856 4 −4 −3 4 1.40251 66.62790 2 4 3 4 1.40178 66.66737 2 −3 −7 4 1.40123 66.69715 5 −2 −7 4 1.40118 66.69978 3 −2 −8 4 1.40053 66.73479 1 −5 −1 4 1.39767 66.88894 3 −4 −5 4 1.39761 66.89248 1 5 0 4 1.39591 66.98464 3 −3 −7 4 1.39498 67.03543 6 −2 −2 4 1.39432 67.07096 2 −2 −8 4 1.39368 67.10576 4 0 4 2 1.39233 67.17963 6 −2 −5 4 1.39218 67.18803 6 0 0 2 1.39146 67.22715 4 −4 −1 4 1.38844 67.39312 4 3 2 4 1.38797 67.41877 5 −1 −8 4 1.37882 67.92709 0 4 5 4 1.37785 67.98154 1 −5 −2 4 1.37724 68.01559 4 −4 −4 4 1.37608 68.08057 1 5 1 4 1.37219 68.30019 0 0 8 2 1.37213 68.30382 0 5 2 4 1.37096 68.37016 1 −3 −7 4 1.36918 68.47118 4 −2 −8 4 1.36910 68.47589 4 1 4 4 1.36616 68.64389 6 1 0 4 1.36534 68.69093 5 3 0 4 1.36303 68.82355 3 4 2 4 1.36190 68.88850 6 −1 −7 4 1.36065 68.96085 2 3 5 4 1.36033 68.97921 2 −5 −1 4 1.35414 69.33989 6 −2 −1 4 1.35205 69.46230 4 −3 −7 4 1.35190 69.47100 1 −2 −8 4 1.35018 69.57237 4 4 0 4 1.34986 69.59140 5 −3 −6 4 1.34938 69.61938 6 −2 −6 4 1.34879 69.65417 1 3 6 4 1.34807 69.69667 2 −5 −2 4 1.34710 69.75419 0 1 8 4 1.34706 69.75684 2 2 6 4 1.34705 69.75717 2 5 0 4 1.34082 70.12915 3 3 4 4 1.34035 70.15689 1 −5 −3 4 1.33737 70.33644 2 −4 −6 4 1.33596 70.42175 3 2 5 4 1.33592 70.42439.

3. The crystalline polymorph of the anhydrous form according to claim 1, further comprising the infrared spectrum FIG. 5.

4. The crystalline polymorph of the anhydrous form according to claim 1, presenting the next IR vibrational frequencies:

C═O stretching at 1656 cm⁻¹; and

azomethine C═N stretching at 1647 cm⁻¹and 1604 cm⁻¹; and

OH stretching at 3396 cm⁻¹; and

NH stretching at 3183 cm⁻¹.

5. The crystalline polymorph of the anhydrous form according to claim 4, further comprising the infrared spectrum FIG. 5.

6. A pharmaceutical composition comprising the anhydrous crystalline polymorph as described in claim 1, 2, 3, 4, or 5, further comprising, at least one of a diluent, an excipient, and any pharmaceutically acceptable vehicle.